PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34665696-7 2021 RESULTS: Baricitinib inhibited OSM-induced JAK signalling in RA synovial fibroblasts and effectively suppressed subsequent expression of the proinflammatory mediators IL-6, MCP-1 and IP-10. baricitinib 9-20 C-C motif chemokine ligand 2 Homo sapiens 173-178 34665696-9 2021 Although both TNFalpha and IL-1beta signal independently of the JAK/STAT pathway, in HSF, but not in RA FLS, baricitinib significantly inhibited TNFalpha- and IL-1beta-induced MCP-1 and IP-10 protein levels in a dose dependent manner. baricitinib 109-120 C-C motif chemokine ligand 2 Homo sapiens 176-181 34248953-11 2021 OSM-induced secretion of MCP-1 and IL-6 was inhibited by all JAKi with Peficitinib, Baricitinib and Upadacitinib showing the greatest effect. baricitinib 84-95 C-C motif chemokine ligand 2 Homo sapiens 25-30 33639176-7 2021 Baricitinib did modulate other soluble factors besides IFN-gamma, significantly decreasing the spike-specific-response mediated by IL-17, IL-1beta, IL-6, TNF-alpha, IL-4, IL-13, IL-1ra, IL-10, GM-CSF, FGF, IP-10, MCP-1, MIP-1beta (p <= 0.0156). baricitinib 0-11 C-C motif chemokine ligand 2 Homo sapiens 213-218 35164829-13 2022 Lastly, adalimumab, baricitinib, and tofacitinib treatment were able to attenuate the pembrolizumab-induced MCP-1 production (P = 0.0004, P = 0.033, and P = 0.025, respectively), while this was not seen with tocilizumab treatment (P = 0.75). baricitinib 20-31 C-C motif chemokine ligand 2 Homo sapiens 108-113